Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination with Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301)

The Phase III ILLUMINATE-301 study evaluated tilsotolimod, a Toll-like receptor-9 agonist, with or without ipilimumab in patients with anti–PD-1 advanced refractory melanoma.